Lilly Moves to Secure Kelonia in $2 Billion Oncology Innovation Play
For Lilly, the strategic rationale is clear. While the company has achieved remarkable commercial success in diabetes and weight-loss therapeutics, it has been simultaneously pursuing diversification into high-growth therapeutic segments.…